Patents by Inventor David M. Holtzman

David M. Holtzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF DETERMINING AMYLOID BETA TURNOVER IN BLOOD
    Publication number: 20170146557
    Abstract: The present invention encompasses a method for determining A? turnover in blood.
    Type: Application
    Filed: February 1, 2017
    Publication date: May 25, 2017
    Inventors: Randall J. Bateman, David M. Holtzman, Kwasi G. Mawuenyega
  • Assay method for Alzheimer's disease
    Patent number: 9453069
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: September 27, 2016
    Assignees: ELI LILLY AND COMPANY, WASHINGTON UNIVERSITY
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • Humanized antibodies that sequester amyloid beta peptide
    Patent number: 8591894
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: November 26, 2013
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Assay Method for Alzheimer's Disease
    Publication number: 20130230513
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Application
    Filed: April 16, 2013
    Publication date: September 5, 2013
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • Assay method for Alzheimer's disease
    Patent number: 8444977
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Grant
    Filed: July 12, 2010
    Date of Patent: May 21, 2013
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • METHODS OF DETERMINING AMYLOID BETA TURNOVER IN BLOOD
    Publication number: 20130115716
    Abstract: A method for determining A.beta. turnover in blood includes the use of a labeled amino acid to assess the turnover rate.
    Type: Application
    Filed: May 24, 2011
    Publication date: May 9, 2013
    Applicant: THE WASHINGTON UNIVERSITY
    Inventors: Randall J. Bateman, David M. Holtzman, Kwasi G. Mawuenyega
  • HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE
    Publication number: 20110158986
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: December 22, 2010
    Publication date: June 30, 2011
    Applicants: ELI LILLY CORPORATION, WASHINGTON UNIVERSITY
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Humanized antibodies that sequester amyloid beta peptide
    Patent number: 7892545
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: February 22, 2011
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • ASSAY METHOD FOR ALZHEIMER'S DISEASE
    Publication number: 20100279433
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Application
    Filed: July 12, 2010
    Publication date: November 4, 2010
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • Assay method for alzheimer's disease
    Patent number: 7771722
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A?40, A?42, their ratio, or their rate of entry following administration of antibodies that sequester A?. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: August 10, 2010
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul
  • HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE
    Publication number: 20090238821
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Application
    Filed: February 8, 2008
    Publication date: September 24, 2009
    Applicant: ELI LILLY CORPORATION
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Humanized antibodies that sequester abeta peptide
    Patent number: 7195761
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13–28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: March 27, 2007
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Diagnostic for early stage Alzheimer's disease
    Patent number: 7015044
    Abstract: A method for diagnosing Alzheimer's disease even at early stages by assessing the levels of sulfatides or its metabolites in biological fluids is disclosed.
    Type: Grant
    Filed: December 10, 2002
    Date of Patent: March 21, 2006
    Assignee: Washington University
    Inventors: Xianlin Han, David M. Holtzman
  • Assay method for alzheimer's disease
    Publication number: 20040248197
    Abstract: A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A&bgr;40, A&bgr;42, their ratio, or their rate of entry following administration of antibodies that sequester A&bgr;. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.
    Type: Application
    Filed: February 17, 2004
    Publication date: December 9, 2004
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, David J. Cummins, Steven M. Paul, Audrey Yunhua Jia, Naoya Tsurushita, Maximiliano J. Vasquez
  • Humanized antibodies that sequester Abeta peptide
    Publication number: 20040043418
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&bgr; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A&bgr;.
    Type: Application
    Filed: August 21, 2002
    Publication date: March 4, 2004
    Inventors: David M. Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez
  • Diagnostic for early stage Alzheimer's disease
    Publication number: 20030180959
    Abstract: A method for diagnosing Alzheimer's disease even at early stages by assessing the levels of sulfatides or its metabolites in biological fluids is disclosed.
    Type: Application
    Filed: December 10, 2002
    Publication date: September 25, 2003
    Inventors: Xianlin Han, David M. Holtzman
  • Predictive diagnostic for Alzheimer's disease
    Patent number: 6465195
    Abstract: A diagnostic method for identifying individuals at risk for developing Alzheimer's disease is disclosed. The method relies on elevated levels of the ratio of A&bgr;40/A&bgr;42 associated with lipoproteins in the cerebrospinal fluid of individuals at risk as compared to this ratio in the overall population.
    Type: Grant
    Filed: December 29, 2000
    Date of Patent: October 15, 2002
    Assignee: Washington University
    Inventors: David M. Holtzman, Anne Fagan Niven
  • Predictive diagnostic for alzheimer's disease
    Publication number: 20010044126
    Abstract: A diagnostic method for identifying individuals at risk for developing Alzheimer's disease is disclosed. The method relies on elevated levels of the ratio of A&bgr;40/A&bgr;42 associated with lipoproteins in the cerebrospinal fluid of individuals at risk as compared to this ratio in the overall population.
    Type: Application
    Filed: December 29, 2000
    Publication date: November 22, 2001
    Inventors: David M. Holtzman, Anne Fagan Niven